Valion Bio, Inc. Employee Benefit and Share-based Payment Arrangement, Noncash
Valion Bio, Inc. (VBIO) reported Employee Benefit and Share-based Payment Arrangement, Noncash of $90.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash · last filed 2025-08-14
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-06-30 was $90.00K, a 66.67% increase year-over-year.
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-03-31 was $100.00K, a 85.19% increase year-over-year.
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2024-09-30 was $58.00K, a 20.83% increase year-over-year.
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2024-06-30 was $54.00K, a 33.33% decline year-over-year.
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2024 was $229.00K, a 15.50% decline from fiscal 2023.
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2023 was $271.00K, a 31.91% decline from fiscal 2022.
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2022 was $398.00K, a 598.25% increase from fiscal 2021.
- Valion Bio, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2021 was $57.00K.
| Period end | Employee Benefit and Share-based Payment Arrangement, Noncash 3 month | Employee Benefit and Share-based Payment Arrangement, Noncash 3 month as first filed | Employee Benefit and Share-based Payment Arrangement, Noncash 6 month | Employee Benefit and Share-based Payment Arrangement, Noncash 9 month | Employee Benefit and Share-based Payment Arrangement, Noncash 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $90.00K 10-Q · filed 2025-08-14 | $190.00K derived: sum of 2 quarters · filed 2025-08-14 | |||
| 2025-03-31 | $100.00K 10-Q · filed 2025-08-14 | ||||
| 2024-12-31 | $229.00K 10-K · filed 2025-03-21 | ||||
| 2024-09-30 | $58.00K 10-Q · filed 2024-11-14 | $112.00K derived: sum of 2 quarters · filed 2025-08-14 | $166.00K derived: sum of 3 quarters · filed 2025-08-14 | ||
| 2024-06-30 | $54.00K 10-Q · filed 2025-08-14 | $108.00K derived: sum of 2 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $54.00K 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | $271.00K 10-K · filed 2025-03-21 | ||||
| 2023-09-30 | $48.00K 10-Q · filed 2024-11-14 | $129.00K derived: sum of 2 quarters · filed 2024-11-14 | $213.00K derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $81.00K 10-Q · filed 2024-11-14 | $165.00K derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $84.00K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $398.00K 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | $113.00K 10-Q · filed 2023-11-14 | $225.00K derived: sum of 2 quarters · filed 2023-11-14 | $286.00K derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $112.00K 10-Q · filed 2023-11-14 | -$112.00K 10-Q · filed 2022-08-15 | $173.00K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $61.00K 10-Q · filed 2023-11-14 | -$61.00K 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $57.00K 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $23.00K 10-Q · filed 2022-11-14 | $31.00K derived: sum of 2 quarters · filed 2022-11-14 | $41.00K derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $8.00K 10-Q · filed 2022-11-14 | -$8.00K 10-Q · filed 2022-08-15 | $18.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $10.00K 10-Q · filed 2022-11-14 | -$10.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |